Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema

Area of Science:

• Ophthalmology
• Endocrinology
• Pharmacology

Background:

• Diabetic macular edema (DME) treatment has evolved with new pharmacotherapies approved since 2012.
• Anti-vascular endothelial growth factor (VEGF) agents are the current gold standard for first-line DME treatment.
• A significant portion of patients exhibit inadequate response to anti-VEGF therapies, necessitating alternative treatment strategies.

Framework:

• Corticosteroids represent a viable treatment option for refractory DME due to their ability to downregulate VEGF and inflammatory cytokines.
• Phase 3 trials (MEAD and FAME) demonstrated visual acuity improvements with dexamethasone and fluocinolone acetonide in DME patients.
• Potential class-specific adverse events, such as increased intraocular pressure and cataract development, are critical considerations for corticosteroid use.

Implementation:

• Expert panel discussions at the American Academy of Ophthalmology meeting focused on optimizing patient selection for corticosteroid therapy.
• Management strategies for adverse events associated with intravitreal corticosteroid implants were a key focus.
• The 0.19 mg fluocinolone acetonide intravitreal implant was specifically discussed in relation to patient selection and adverse event management.

Implications:

• Understanding the multifaceted pathology of DME is crucial for tailoring treatment approaches.
• Personalized medicine in DME management involves balancing efficacy with the risk of adverse events.
• Continued research and expert consensus are vital for refining DME treatment guidelines and improving patient outcomes.